PEREZ, MD: “We are encouraged by the results. Perez, MD, Director of the Breast Cancer Program and Professor of Medicine in the Division of Hematology/Oncology at the Mayo Clinic in Jacksonville, FL.ĮDITH A. All participants had HER2-positive metastatic cancer, with no prior chemotherapy for their metastatic disease.Īt a median follow-up of six months, the overall response rate was about 48% in the T-DM1 arm, compared with about 41% in the trastuzumab-plus-docetaxel arm, reported Edith A. In the trial, which was funded by the drug's manufacturer, Genentech, researchers randomly assigned 137 women to treatment with trastuzumab plus docetaxel, or T-DM1. Krop, who is also studying T-DM1, but was not involved with this work. And trastuzumab still does all the things that trastuzumab does,” said Dr. “The cytotoxic drug goes right to the cancer cells so it's not floating around and causing other problems. Krop, MD, Assistant Professor of Medicine at Harvard Medical School and a medical oncologist at Dana-Farber Cancer Institute's Breast Oncology Center. The DM1 molecules form a very stable bond with trastuzumab so that DM1 is not released until trastuzumab finds cells that have HER2 overexpression, explained Ian E. T-DM1 is an antibody-drug conjugate, designed for the targeted intracellular delivery of the potent anti-microtubule derivative DM1 via the highly specific monoclonal antibody trastuzumab. In the Phase II study, presented at the European Society for Medical Oncology Congress, the antibody-drug conjugate produced a better response rate and significantly reduced the rate of side effects among patients with HER2-positive metastatic breast cancer. The investigational drug trastuzumab-DM1 (T-DM1) outperformed standard therapy in patients with advanced breast cancer, according to results of the first randomized, head-to-head trial of T-DM1 versus trastuzumab plus a taxane in first-line, advanced, HER2-positive breast cancer.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |